Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer
ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?
You may also be interested in...
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.
Cadila Healthcare has launched a generic version of Astellas/Pfizer’s prostate cancer therapy Xtandi in India at a sharp discount of 70-90% to existing brands and hopes the lower financial burden on patients will aid adherence.
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.